The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Kartos Therapeutics
Leadership - Kartos Therapeutics
Stock and Other Ownership Interests - Kartos Therapeutics
Travel, Accommodations, Expenses - Kartos Therapeutics
BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in TP53WT relapsed/refractory (R/R) myelofibrosis (MF).
 
Srdan Verstovsek
Consulting or Advisory Role - Celgene; Constellation Pharmaceuticals; Incyte; Novartis; Sierra Oncology
Research Funding - Blueprint Medicines; Celgene; CTI BioPharma Corp; Genentech; Gilead Sciences; Incyte; Novartis; NS Pharma; Promedior; Roche
 
Haifa Kathrin Al-Ali
Honoraria - Bristol-Myers Squibb; Novartis
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis; Pfizer
Research Funding - Incyte (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
 
John Mascarenhas
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Constellation Pharmaceuticals; Geron; Incyte; Kartos Therapeutics; Roche
Research Funding - CTI (Inst); Forbius (Inst); Incyte (Inst); Janssen (Inst); Merck (Inst); PharmaEssentia (Inst); Promedior (Inst); Roche (Inst)
 
Adam J. Mead
Honoraria - Abbvie; Celgene/Bristol-Myers Squibb; CTI; Gilead Sciences; Novartis
Consulting or Advisory Role - Abbvie; Celgene/Bristol-Myers Squibb; CTI; Gilead Sciences; Novartis
Speakers' Bureau - Novartis
Research Funding - Celgene/Bristol-Myers Squibb (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Celgene/Bristol-Myers Squibb; Novartis
 
Andrew Perkins
Honoraria - Celgene; Novartis
Consulting or Advisory Role - Novartis
Speakers' Bureau - Novartis
Travel, Accommodations, Expenses - Novartis
 
Alessandro M. Vannucchi
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Celgene; Geron; Incyte; Novartis
Speakers' Bureau - Abbvie; Bristol-Myers Squibb; CTI; Incyte; Novartis
 
Anne Uyei
Employment - Kartos Therapeutics
Stock and Other Ownership Interests - Kartos Therapeutics; Roche; Telios
 
Wayne P. Rothbaum
Leadership - Iovance Biotherapeutics; Kartos Therapeutics; Telios
Stock and Other Ownership Interests - Acerta Pharma; Iovance Biotherapeutics; Kartos Therapeutics; Telios
Patents, Royalties, Other Intellectual Property - Acerta Pharma; Kartos Therapeutics; Telios
Travel, Accommodations, Expenses - Iovance Biotherapeutics; Kartos Therapeutics; Telios
 
Jesse McGreivy
No Relationships to Disclose
 
Jean-Jacques Kiladjian
Consulting or Advisory Role - Abbvie; AOP Orphan Pharmaceuticals; Bristol-Myers Squibb; Incyte; Novartis; PharmaEssentia